Study details
Enrolling now
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
University of California, San Diego
NCT IDNCT06586281ClinicalTrials.gov data as of Apr 2026
Target enrollment
20
Study length
about 1.5 years
Ages
All ages
Locations
1 site in CA
What this study is about
Researchers are testing whether a treatment called guselkumab can help people with psoriasis who also have nonalcoholic fatty liver disease (NAFLD) improve their joint pain, skin problems, and liver health. The trial will last for 548 days and involve approximately 20 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Guselkumab
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
guselkumab
Drug routes
injection, intravenous
Endpoints
Secondary: Change from baseline in skin psoriasis severity, Change in ALT Levels
Body systems
Dermatology